Yermak’s Resignation Sends Shockwaves Through Kyiv and Europe
The resignation of Andriy Yermak after anti-corruption raids disrupts Ukraine’s leadership and triggers uncertainty across Europe during a critical phase of the war.
The Russell Group has picked Professor Libby Hackett, an Australia based public policy specialist, as its next chief executive, handing the UK’s most influential research university lobby to a leader with deep experience in government facing policy work and sector politics.
The resignation of Andriy Yermak after anti-corruption raids disrupts Ukraine’s leadership and triggers uncertainty across Europe during a critical phase of the war.
After weeks of tax rumour and expectation-setting, the 26 November Budget landed as a welfare-first package that lifts the benefits cap but tightens the screw on household incomes,
Two long-serving members of the House of Lords have been suspended after an official inquiry found they provided parliamentary services in return for commercial gain.
The European Parliament on 13 November 2025 approved amendments that sharply reduce the scope of the Corporate Sustainability Due Diligence Directive and the associated reporting regime
The FTSE 100 hit a record 9,787 points as investors cheered progress in Washington towards ending the US government shutdown. Strong gains in Diageo, miners and financial stocks
Reappointed French Prime Minister Sébastien Lecornu unveiled his second cabinet and must deliver the 2026 budget within days. With opposition parties preparing a no-confidence motion and markets showing
As Ukraine rebuilds from war, music is emerging as a vital force for healing, unity and national renewal.
Optimism, strategy and late-night gossip: Beverley Nielsen shares her experience of Labour’s four-day conference in Liverpool.
Mega‑mergers are surging in 2025, with Q3 deal values exceeding $1 trillion. Big names include Union Pacific’s $85 billion rail deal, Synopsys acquiring Ansys, and the creation of Paramount Skydance.
The UK government is reportedly prepared to allow higher NHS medicine prices to defuse U.S. threats of 100 percent tariffs on branded drugs. The shift comes as pharmaceutical firms